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ABSTRACT 
 Obesity is widely correlated with the incidence of colorectal cancer (CRC).  The 
exact mechanisms that link obesity to CRC risk have not yet been fully established, and 
only a limited number of animal models are available to study pathways involved in 
obesity-related colon carcinogenesis.  The objective of this study was to determine the 
influence of HFD-induced obesity on AOM/DSS-mediated colorectal tumorigenesis, 
tumor proliferation, and symptom severity.  Male C57BL/6 mice were fed a novel high 
fat diet, designed to mimic the standard American diet (12 % saturated fat & 28 % 
unsaturated fat), at 4 weeks of age until 16 weeks of age to induce obesity.   At 16 weeks 
of age HFD-fed mice had significantly increased mean body mass compared to LFD-fed 
mice. Thus, mice were obese prior to initiation of CRC.  Following treatment with 
AOM/DSS, study results indicated no significant changes in tumor number or size with 
obesity.  Similarly, obesity did not increase the severity of symptoms in this model. 
These findings challenge previously published data, with the caveat that the low number 
of tumors detected in the present model limits translational implications for tumor 
characteristics and symptom severity in obesity. 
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As the second leading cause of cancer-related deaths for both men and women in 
the United States, colorectal cancer (CRC) is a national burden.  It is the third most 
commonly diagnosed cancer and is of increasing health concern to a growing aging 
population 1,2.   It has been shown in epidemiological studies that obesity and metabolic 
syndromes, like hyperglycemia, hypertension, and hyperlipidemia, increase the risk of 
developing CRC 3.  As such, lifestyle factors such as limited physical activity, 
consumption of food with high fat/limited fiber content, high caloric intake, and obesity 
are controllable factors that can influence the development of CRC 4.  Conversely, it has 
been demonstrated that behavioral factors like exercise and consumption of fruits and 
vegetables, even among obese individuals, can reduce the incidence of CRC 4.  While 
family history is a large component in determining CRC risk, environmental factors are 
responsible for the majority of cases.  In fact, sporadic CRC, the most prominent form of 
CRC that occurs due to an accumulation of mutations in genes regulating the growth and 
proliferation of colonic epithelial cells is influenced largely by environmental factors 
independent of genetic background 5. 
Obesity is widely correlated with the incidence of CRC 6.  The exact mechanisms 
that link obesity to CRC risk have not yet been fully elucidated; however, a number of 
biochemical changes associated with obesity have been implicated and include 
inflammatory mediators, adipokines and metabolic markers among others.  For example 
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leptin that is upregulated in obese individuals is a hormone and cytokine produced 
primarily by adipocytes has been shown to induce CRC by a variety of different 
pathways 4.  Similarly, increased plasma levels of insulin observed during obesity disrupt 
normal metabolic processes and thought to activate pathways involved in oncogenesis 4.  
In addition, inflammatory mediators that are increased in adipose tissue have been linked 
to every step involved in the development and promotion of CRC. While there is an 
abundance of obesity-mouse models, the number of models available to study pathways 
involved in colon carcinogenesis is limited 3. 
Among the chemically induced CRC models, the azoxymethane (AOM) and 
dextran sodium sulfate (DSS) model has been proven to induce CRC in a shortened 
amount of time with a high level of reproducibility 7.  This outstanding model has been 
utilized in a variety of studies investigating the histopathologic and molecular features 
involved in carcinogenesis as well as determining chemopreventive and therapeutic 
approaches in combating CRC 7.  The purpose of this current investigation was to 
examine the effects of high fat diet induced obesity on CRC.  In this study, male 
C57BL/6 mice were fed a novel high fat diet, designed to mimic the standard American 
diet (12 % saturated fat & 28 % unsaturated fat), at 4 weeks of age until 16 weeks of age 
to induce obesity.   At 16 weeks of age mice were exposed to the CRC protocol.  Thus, 
mice were obese prior to initiation of CRC.  This clinically relevant model aims to mimic 
the conditions of tumor initiation and progression that occurs in obese humans.  Previous 
studies have co-induced obesity and CRC with the AOM/DSS protocol; however, this 
approach fails to account for the conditions observed in the at risk obese population prior 
to the onset of colon cancer.  We hypothesized that obesity induced prior to initiation of 
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CRC would lead to increased severity of sickness symptoms in association with enhanced 
tumorigenesis.  A better understanding of the impact of obesity on CRC is necessary in 





MATERIALS & METHODS  
2.1 ANIMALS 
Male C57BL/6 mice, 4 weeks of age, were purchased from Jackson Laboratories 
(Bar Harbor, ME) and cared for in the animal facility at the University of South Carolina.  
They were housed four-five per cage and maintained on a 12:12-hr light-dark cycle in a 
low stress environment (22°C, 50% humidity, low noise) and given food and water ad 
libitum.  All animal experimentation was approved by the University of South Carolina's 
Institutional Animal Care and Use Committee.   
2.2 DIETS 
Mice were randomly assigned to one of five treatment groups as follows: 1) Low 
Fat Diet-Control (LFD-Con), 2) High Fat Diet-Control (HFD-Con), 3) Low Fat Diet-
Colorectal Cancer (LFD-CRC), 4) High Fat Diet-Colorectal Cancer Group 1(HFD-CRC-
1) or 5) High Fat Diet-Colorectal Cancer Group 2 (HFD-CRC-2).  HFD-CRC-1 and 
HFD-CRC-2 differed in the dose of azoxymethane (AOM) that was administered to 
initiate the cancer; group 1 received a dose of AOM based on body weight (10mg/Kg) 
whereas group 2 received a dose of AOM that was equivalent to the LFD-CRC group.   
This was done in order to eliminate any potential differences among the groups due to the 
dose of AOM.  The HFD (12% saturated fat & 28% unsaturated fat) was designed to 
mimic the standard American Diet (Bio-Serv, Frenchtown, NJ) (Table 2.1).  The AIN-
76A diet was used as the LFD (Bio-Serv).  Diets were administered beginning at 4 weeks
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of age through sacrifice at 26 weeks of age. The HFD retained the same vitamin and 
mineral content as the control diet.  Food and water was available ad libitum and 
measured on a weekly basis. 
2.3 BODY WEIGHT & BODY COMPOSITION 
Body weight was examined weekly beginning at 4 weeks of age and for the 
duration of the 22 week study.  In addition, body composition was assessed at 16 weeks 
of age (prior to initiation of the CRC protocol) and at 26 weeks of age (prior to sacrifice).  
For this procedure, mice were placed under brief anesthesia (isoflurane inhalation) and 
were assessed for lean mass, fat mass, and body fat percentage via dual-energy x-ray 
absorptiometry (DEXA) (Lunar PIXImus, Madison, WI).   
2.4 COLORECTAL CANCER PROTOCOL 
To induce colorectal cancer, mice in the CRC groups underwent a standard 
protocol consisting of a single subcutaneous injection of azoxymethane (AOM) at 16 
weeks of age, followed by 3 cycles of DSS (2% DSS in water for one week followed by 
two weeks of regular water for the first cycle and 1% DSS in water for the second and 
third cycles) beginning at week 17.  Both the LFD-CRC and the HFD-CRC-1 groups 
received a dose of AOM based on their body weight (10mg/Kg body weight) whereas 
HFD-CRC-2 received a dose of AOM that was equivalent to the LFD-CRC group.   As 
mentioned above, this was done in order to eliminate any potential differences among the 
groups due to the dose of AOM (i.e. an increase in tumor number with HFD that may be 
due to the increased concentration of AOM that was administered to these mice given 
their increased weight). 
2.5 SYMPTOM SCORING 
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Symptoms were scored twice weekly throughout the 10 week protocol using a 
standard scoring system that has previously been used in this model.  Briefly, scores were 
based on diarrhea, blood in stools and weight loss.  Diarrhea symptoms were evaluated 
based on visualization of the fecal matter.  Blood in the stools was determined using a 
Hemoccult Fecal occult blood test.  Weight loss was based on the percent change in 
weight compared to baseline levels.   Mice were given scores of 0, 2 or 4 depending on 
the severity of the symptoms. 
2.6 SACRIFICE & TISSUE COLLECTION 
At 26 weeks of age, mice were sacrificed for tissue collection via isofluorane 
overdose.  The kidney fat, mesenteric fat and epididymal fat were removed, weighed, and 
immediately snap-frozen in liquid nitrogen and stored at -80°C.  The large intestine was 
dissected from the cecum to the anus and placed on filter paper.  A large needle and 
syringe was used to flush the large intestine with PBS.  The large intestine was then cut 
longitudinally, flattened with a cotton swab saturated with PBS, and another filter paper 
was placed on top of the sections. The filter paper was then sandwiched between two 
pieces of blotting paper, clipped together on all four sides, and subsequently fixed in 10% 
formalin for at least 24 hours. After that time, the sections were transferred and stored in 
70% ethanol at room temperature to be further analyzed for tumor number and size. 
2.7 TUMOR COUNTS 
To count tumors, the large intestines were rinsed in deionized water, and briefly 
stained in 0.1% methylene blue.  Tumors were counted by the same blinded technician 
for all samples under a dissecting microscope, using tweezers to pick through the villi to 
identify tumors.  Tumors were classified as being greater than 2mm, less than 2mm but 
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greater than 1mm, or less than 1mm in diameter using an ocular micrometer.  Colon 
lengths were measured as an indicator of inflammation; a shorter colon length is 
indicative of greater inflammation.   Similarly, colon weight was determined as an 
increase in colon weight has been associated with elevated inflammation. 
 
 









3.1 BODY WEIGHT & BODY COMPOSITION 
Body composition was calculated by DEXA and lean mass, percent lean mass, 
total body fat, and body fat percent were determined (Figure 3.1).  The mice consuming 
the HFD had significantly elevated body fat and percent body fat relative to LFD-fed 
mice by 16 weeks of age (following 12 weeks of HFD feedings and prior to initiation of 
CRC), thus HFD-fed mice were obese prior to induction of CRC at 16 weeks of age 
(P≤.05).  While we observed a general increase in lean mass at sacrifice compared to 
baseline for all groups, the percent lean mass for HFD-fed mice was significantly reduced 
relative to the LFD-fed mice (P≤.05).  Conversely, body fat and percent body fat at 
sacrifice were significantly increased versus baseline in all the HFD groups.   
Interestingly, at sacrifice the LFD-CRC mice had significantly lower body fat and body 
fat percent than the LFD-Con, but the HFD-CRC-1 & 2 mice had significantly increased 
body fat and body fat percent compared to HFD-Con mice.  
Body weight was monitored twice weekly throughout the 10 week AOM/DSS 
protocol and was expressed as a percent of baseline (i.e. normalized to measured body 
weight prior to the initiation of the AOM/DSS protocol) (Figure 3.2A).  The LFD-Con 
and HFD-Con groups maintained a greater rate of body weight gain during the course of 
treatment and these groups were different from each other at most time-points.  However, 
as expected, an overall decrease in body weight in the LFD-CRC group was observed
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from weeks 17.5 to 22 and was significantly different from all other groups (P≤.05).  The 
HFD-CRC-1 & 2 groups had a significantly greater increase in percent change in body 
weight than the LFD-CRC group from 17.5 weeks to 22 weeks (P≤.05).   
3.2 SYMPTOM SEVERITY 
Symptom scores were calculated twice weekly throughout the 10-week protocol 
and were based on diarrhea, blood in stools and body weight loss (Figure 3.2B).  
Symptom scores in all groups followed the same general trend; there was an increase in 
symptom score during each week of DSS treatment, which dropped in the subsequent 2 
weeks during the water cycle.  The only significant increase in symptom severity score 
was observed in LFD-CRC mice compared to HFD-CRC-2 mice at week 18.5 (P≤.05). 
3.3 FOOD & FLUID INTAKE 
It was not possible to calculate individual food intake, as mice were housed 4-
5/cage.  However, in general, we did not observe any differences among the HFD-fed 
mice in weekly food intake (i.e food consumed by mice in each cage/number of mice in 
cage) over the course of the study.   
3.4 TISSUE WEIGHTS 
Fat pads were collected at sacrifice and for all fat pad depots, the HFD-fed mice 
had enhanced fad pad mass compared to the LFD-fed mice (Figure 3.3) (P≤.05).  Both 
HFD-CRC-1 & 2 groups had a significantly greater epididymal fat pad mass than HFD-
Con mice; however, the HFD-CRC-1 & 2 groups had reduced mesentery fat pads relative 
to HFD-Con. 
Spleens were collected and weighed at sacrifice (Figure 3.4).  In general, spleen 
weight, expressed as a percent of body weight, increased in all CRC groups as compared 
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to the control HFD and LFD mice and this reached significance when LFD-CRC mice 
were compared to HFD-Con mice (P≤.05).  
3.5 TUMOR COUNTS 
 At sacrifice, colons were harvested and tumors were counted on formalin-fixed, 
methylene blue-stained sections.  No significant differences between groups were 
determined; however, the number of polyps in the LFD-CRC and HFD-CRC-2 groups 
was elevated compared to HFD-CRC-1 (Figure 3.6).  Colon length and weight were 
measured following fixation.   No significant differences were observed between groups 





Figure 3.1 DEXA body composition collected at baseline (16 weeks of age) and at 
sacrifice (26 weeks of age) on (A) lean mass and BMC, (B) body fat, (C) % lean mass 
and BMC, (D) % body fat.  *Significantly different from LFD




HFD-Con (P≤.05).  $Significantly different from LFD-
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Figure 3.2 The impact of HFD and CRC on (A) percent change in body weight.  
*Significantly different from LFD-Con (week 17.5-18: HFD-Con & LFD-CRC; week 
18.5-19: HFD-Con, LFD-CRC, & HFD-CRC-1 & 2; week 19.5-21.5: HFD-Con, LFD-
CRC, & HFD-CRC-1; week 22-24.5: HFD-Con & LFD-CRC; week 25-26: HFD-Con, 
LFD-CRC, & HFD-CRC1&2; P≤.05)  #Significantly different from HFD-Con (week 
16.5-17: LFD-CRC; week 17.5-26: LFD-CRC & HFD-CRC-1&2; P≤.05).  
$Significantly different from LFD-CRC (week 17.5-26: HFD-CRC-1&2; P≤.05). (B) 
The effect of DSS induced inflammation on symptom scores.  $Significantly different 
from LFD-CRC (week 18.5: HFD-CRC-2 only; P≤.05) 
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Figure 3.3 The effect of HFD and CRC on (A) epididymal, (B) mesentery, 
(C) kidney, and (D) total visceral (Total) fat pad weights at sacrifice. 
*Significantly different from LFD-Con (P≤.05). #Significantly different from 
HFD-Con (P≤.05).  $Significantly different from LFD-CRC (P≤.05) 
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 Figure 3.4 Spleen weight at sacrifice as a measure of inflammation and CRC 
immune response. #Significantly different from HFD-Con (P≤.05) 
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 Figure 3.5 The effect of CRC and DSS induced inflammation on (A) colon length 
and (B) colon weight.  *Significantly different from LFD-Con (P≤.05). 





Figure 3.6 The impact of CRC induction at sacrifice for (A) total polyp number & (B) 
total polyp number by size.  No significant differences between any groups 
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CRC is the second leading cause of cancer related deaths worldwide and is a 
serious public health concern.  Lifestyle factors, such as obesity, smoking, high caloric 
intake and physical inactivity, have been linked to increased mortality in CRC cases and 
are controllable factors in the prevention of CRC development and progression 7.  
Clinical studies suggest that up to 20% of all cancers are attributed to obesity.  Further, it 
has been well characterized that obesity is widely correlated with the incidence of CRC 7.  
In addition, obesity is largely responsible for poorer oncologic outcomes in CRC 
treatment and management 7.  Our novel study examined the impact of HFD-induced 
obesity in a mouse model of CRC by initiating obesity prior to colon carcinogenesis and 
is thus, clinically relevant to the human obese population at risk for developing CRC. 
However, we did not find any significant changes in tumor number or size with obesity.  
Similarly, obesity did not increase the severity of symptoms in this model.   
Currently, AOM/DSS-induced carcinogenesis in animal models is widely 
accepted and offers a reliable, reproducible, and time-effective approach for the study of 
colonic tumorigenesis 7.   Previous studies have utilized this model to investigate the link 
between obesity and colonic/colitis-related carcinogenesis.  It is well established that 
adipocytes regulate inflammatory processes and secrete proinflammatory cytokines, 
which have been linked to increased proliferation of colonic epithelial cells and 
facilitation of a microenvironment prone to tumor development 8.  For example, Park et
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al. showed that HFD induced obesity in a colitis-related tumorigenesis model increased 
tumor formation and revealed that adiposity-associated inflammation contributes to 
colonic epithelial cell carcinogenesis 9.  In addition, the AOM/DSS model has been 
widely used to explore potential chemopreventive and therapeutic agents in the treatment 
of obesity and colitis-related colonic carcinogenesis 8. 
In our study, male C57BL/6 mice were fed either a LFD (AIN-76A) or HFD 
(12% saturated fat and 28% unsaturated fat) at 4 weeks of age and placed in one of five 
groups (LFD-Control, HFD-Control, LFD-CRC, HFD-CRC-1, and HFD-CRC-2). The 
HFD was designed to be similar to the American standard diet; we previously 
demonstrated that this diet led to increased adiposity, macrophage infiltration, and insulin 
resistance in obese mice 10.  As such, in our study, we observed that at 16 weeks of age 
the HFD-fed mice had significantly increased mean body mass compared to LFD-fed 
mice, thus were obese prior to administration of AOM/DSS treatment (P≤.05).  Enos et 
al. and others have shown that varying saturated fatty acid composition leads to an 
increased risk of obesity and can differentially regulate inflammatory processes, thus it is 
now widely accepted that high-fat-diet-induced obesity can lead to a chronic state of low-
grade inflammation 10.  Although inflammatory processes were not measured in the 
current investigation, we expected that obesity-induced inflammation following 
administration of this diet, would contribute to the hypothesized effects of increased 
tumorigenesis with obesity.   
DSS, a proinflammatory agent, accelerates tumor growth and proliferation when 
instituted following an intraperitoneal injection of AOM by promoting cell growth in the 
epithelial lining of the colon while also halting apoptosis 7.  Similarly, inflammation, as 
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seen in inflammatory bowel disease and Crohn’s disease, also contribute to the 
development of CRC through various mechanisms that disrupt cellular function and 
regulation 11.  We observed in the weeks following treatment with DSS that the sickness 
symptoms in all the AOM/DSS groups was lower than expected and remained diminished 
over the remainder of the study.  This decrease in sickness symptoms over time is 
consistent with previous reports; in a comprehensive review by De Robertis et al., it was 
reported that severe colitis is observed in the week following initial administration of 
DSS but its severity is diminished in subsequent weeks 7.  Contrary to expectations 
though, we did not find an increase in symptom severity in the HFD groups.  Similarly, at 
sacrifice, the colon length in the AOM/DSS treated groups did not decrease, suggesting 
little to no inflammation.  A decrease in colon length is a characteristic feature observed 
in an inflamed colon, therefore these findings were unexpected.  Further, tumor number 
was quite low and there were no differences in tumor size or tumor numbers with HFD.  
In a recent series of studies we conducted on colitis-related colon carcinogenesis, 2% 
DSS was administered in all three treatment cycles; however, a high number of fatalities 
prior to sacrifice limited the scope of the study. In this study, we subsequently reduced 
the dosage of DSS to 2%, 1%, and 1% at weeks 17, 20, and 23, respectively; however, 
contrary to what was expected, we found tumor numbers to be lower than those reported 
in the literature.  These findings of a failure to find a detrimental effect of obesity on 
tumorigenesis in this model should be interpreted with caution; it is certainly possible 
that low tumor numbers precluded our ability to find changes in tumor characteristics 
across the groups.    
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A possible explanation for the discrepancy in inflammation and CRC tumor 
development may be the difference in the dosage of DSS.  It has been established that the 
risk of developing CRC is positively correlated with the degree of inflammation within 
the colon and the duration of the inflammatory disease state. A DSS dosage study 
conducted with AOM-induced CRC carcinogenesis reported that 2% DSS treatment 
resulted in the highest number of colorectal adenocarcinomas 12.  Similarly, it was also 
reported that inflammation scores were higher in mice receiving 2% DSS, suggesting 
there is a tumor-promoting activity in DSS 12. As inflammation is necessary in the 
induction of tumor formation, this may help to explain the minimal number of tumors 
observed in our model. In addition, it is worthwhile mentioning that the body weight and 
age of mice at time of AOM/DSS treatment were greater than those reported in previous 
models, which may have also contributed to the observed findings. Another possible 
rationale for the inconsistent tumor number and inflammatory symptom severity may be 
due to the extent of excess fat accumulation at the time of AOM/DSS treatment.  While 
obesity is generally understood to have a proinflammatory effect in the colon, our results 
suggest that obesity may have some protective role in the initiation of CRC.  This affirms 
the need for future research utilizing HFD-induced obesity models to better understand 
the relationship between obesity and colorectal tumorigenesis.  
In summary, we examined the influence of HFD-induced obesity on 
inflammatory-mediated colorectal tumorigenesis, tumor proliferation, and symptom 
severity.  In general, there was no increase in symptom severity with HFD-induced 
obesity.  Similarly, in regard to tumor number, our findings are contradictory to 
previously published data that ad libitum, high-fat diet induced obesity leads to an 
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increased risk of CRC development. However, our findings should be interpreted with 
caution; it is certainly possible that low tumor numbers precluded our ability to find 
changes in tumor characteristics and symptom severity with obesity.   Although obesity 
has implications of having proinflammatory and carcinogenic outcomes in the colon, 
future research should examine the degree to which HFD induced obesity impacts 
metabolic disruption, pro-inflammatory signaling, and subsequent initiation and 
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